A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

To join this study, you must be an adult aged 18 or over. You need to have a long-term Hepatitis Delta infection that is currently active, meaning your virus levels are above a certain point and your liver enzyme (ALT) levels are also abnormal. You must also be willing to take or already be taking medicine for Hepatitis B, as these two infections often go hand-in-hand.

There are also some reasons why you might not be able to join. For instance, if you are pregnant or breastfeeding, or if you can't or won't use birth control during the study. You also can't have other serious liver problems besides Hepatitis B or Delta, like certain types of fatty liver disease or liver cancer. If you have serious signs of liver failure, like fluid in your belly or confusion, or if you've had an organ transplant, you also wouldn't be able to take part.

If you decide to take part in this study, you will be assigned to one of three groups. Two groups will start taking the study medicine, Brelovitug, right away. One of these groups will get 300 mg once a week, and the other will get 900 mg once every four weeks. The medicine is given as an injection under the skin.

The third group will wait 24 weeks before starting the medicine. During this waiting period, you will still come to the clinic for regular check-ups, blood tests, and other health assessments, just like the groups taking the medicine. After these 24 weeks, everyone in this group will then start taking Brelovitug 300 mg once a week.

Throughout the study, regardless of which group you are in, you will have regular visits to the clinic for various tests. These include blood tests to check your liver and virus levels, and other health evaluations. The study will continue for a period to properly assess the effects of the treatment. The total duration of your participation will depend on the study design, but you should expect continued monitoring after you start treatment.